DMT Adherence While Pregnant Is Tied to Lower Medical Costs

Women diagnosed with multiple sclerosis (MS) and being treated with disease-modifying therapies (DMTs) who become pregnant often discontinue those agents, as none are approved for use during pregnancy. But a recent study by AllianceRx Walgreens Prime, in conjunction with parent company Walgreens, demonstrates that when these women remain adherent to DMTs, this may reduce their nonmaternity inpatient and outpatient costs.

The findings were presented at the virtual Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2021, which was held at the end of February.

Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

a-businessman-touching-screen
May 12

Do Pharma/PBM Contracts Play Role in Drugmakers’ Revenue Leakage?

READ MORE
a-doctor-speaking-to-a-patient
May 12

Novartis’ Pluvicto Brings New Mechanism of Action to mCRPC Options

READ MORE
an-elderly-looking-outside
May 12

Study Finds PBC Drug’s Real-World, Trial Side Effects Are Similar

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today